Refractory fallopian tube carcinoma &amp;ndash; current perspectives in pathogenesis and management

Sama, Ashwin R.; Schilder, Russell J.

doi:10.2147/ijwh.s40889

Cited by 3 publications

(1 citation statement)

References 99 publications

(136 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PFTC and EOC bear clinical and histological resemblance, although the former recurs in retroperitoneal nodes and distant sites more often than the latter [ 15 , 16 , 17 ]. Treatment of PFTC is similar to that of EOC, and it includes a total abdominal hysterectomy and omentectomy, followed by adjuvant taxane- and platinum-based chemotherapy, as well as radiotherapy [ 18 , 19 , 20 , 21 , 22 , 23 ]. Previous studies suggested that patients with serous PFTC are eligible for clinical trials designed for those with serous EOC [ 3 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma

et al. 2015

View full text Add to dashboard Cite

Fallopian adenocarcinoma is a rare malignancy arising in the epithelium of the fallopian tube. Fallopian tube epithelium has been proposed as a tissue origin for high-grade serous ovarian carcinoma, the deadliest gynecologic malignancy. Given the commonalities in dissemination and treatment of these malignancies, we contemplated the possibility of similar patterns of gene expression underlying their progression. To reveal potential similarities or differences in the gene expression of fallopian adenocarcinoma and high-grade serous ovarian carcinoma, we tested expression of the fractalkine receptor (CX3CR1) and its ligand, fractalkine (CX3CL1), in the specimens of normal and pathologic fallopian tube using immunohistochemistry. Our data show that CX3CR1 is expressed in the normal, cancer adjacent normal, inflammatory, and malignant fallopian epithelium. CX3CL1 was expressed only by the normal and cancer adjacent normal fallopian tube epithelium; its expression was largely lost in the inflammatory and malignant fallopian epithelium. In opposite, both CX3CR1 and CX3CL1 are expressed in high-grade serous ovarian carcinoma. These findings are consistent with an idea that fallopian adenocarcinoma and high-grade serous ovarian carcinoma, although currently thought to arise from the same organ, may not share similar molecular characteristics.

show abstract

Section: Introductionmentioning

confidence: 99%

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

Kotsopoulos

Lubiński

Gronwald

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

The role of the lifetime number of ovulatory cycles has not been evaluated in the context of BRCA – associated ovarian cancer. Thus, we conducted a matched case-control study to evaluate the relationship between the cumulative number of ovulatory cycles (and contributing components) and risk of developing ovarian cancer in BRCA mutation carriers (1,329 cases and 5,267 controls). Information regarding reproductive and hormonal factors was collected from a routinely administered questionnaire. Conditional logistic regression was used to evaluate all associations. We observed a 45% reduction in the risk of developing ovarian cancer among women in the lowest vs. highest quartile of ovulatory cycles (OR = 0.55; 95%CI 0.41–0.75 P=0.0001). Breastfeeding for more than 12 months was associated with a 38% (95%CI 0.48–0.79) and 50% (95%CI 0.29–0.84) reduction in risk among BRCA1 and BRCA2 mutation carriers, respectively. For oral contraceptive use, maximum benefit was seen with five or more years of use among BRCA1 mutation carriers (OR = 0.50; 95%CI 0.40–0.63) and three or more years for BRCA2 mutation carriers (OR = 0.42; 95%CI 0.22–0.83). Increasing parity was associated with a significant inverse trend among BRCA1 (OR = 0.87; 95%CI 0.79–0.96; P-trend=0.005) but not BRCA2 mutation carriers (OR 0.98; 95%CI 0.81–1.19; P-trend=0.85). A later age at menopause was associated with an increased risk in women with a BRCA1 mutation (OR trend = 1.18; 95%CI 1.03–1.35; P =0.02). These findings support an important role of breastfeeding and oral contraceptive use for the primary prevention of ovarian cancer among women carrying BRCA mutations.

show abstract

Hereditary Ovarian Cancer: Not OnlyBRCA1 and 2 Genes

Toss

Tomasello

Razzaboni

et al. 2015

BioMed Research International

197

118

View full text Add to dashboard Cite

More than one-fifth of ovarian tumors have hereditary susceptibility and, in about 65–85% of these cases, the genetic abnormality is a germline mutation in BRCA genes. Nevertheless, several other suppressor genes and oncogenes have been associated with hereditary ovarian cancers, including the mismatch repair (MMR) genes in Lynch syndrome, the tumor suppressor gene, TP53, in the Li-Fraumeni syndrome, and several other genes involved in the double-strand breaks repair system, such as CHEK2, RAD51, BRIP1, and PALB2. The study of genetic discriminators and deregulated pathways involved in hereditary ovarian syndromes is relevant for the future development of molecular diagnostic strategies and targeted therapeutic approaches. The recent development and implementation of next-generation sequencing technologies have provided the opportunity to simultaneously analyze multiple cancer susceptibility genes, reduce the delay and costs, and optimize the molecular diagnosis of hereditary tumors. Particularly, the identification of mutations in ovarian cancer susceptibility genes in healthy women may result in a more personalized cancer risk management with tailored clinical and radiological surveillance, chemopreventive approaches, and/or prophylactic surgeries. On the other hand, for ovarian cancer patients, the identification of mutations may provide potential targets for biologic agents and guide treatment decision-making.

show abstract

Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management

Cited by 3 publications

References 99 publications

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

Hereditary Ovarian Cancer: Not OnlyBRCA1 and 2 Genes

Contact Info

Product

Resources

About